CN108883101A - 野靛碱的琥珀酸盐及其用途 - Google Patents

野靛碱的琥珀酸盐及其用途 Download PDF

Info

Publication number
CN108883101A
CN108883101A CN201780009979.0A CN201780009979A CN108883101A CN 108883101 A CN108883101 A CN 108883101A CN 201780009979 A CN201780009979 A CN 201780009979A CN 108883101 A CN108883101 A CN 108883101A
Authority
CN
China
Prior art keywords
succinate
cydidine
salt
lactose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780009979.0A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·克拉克
理查德·阿利斯泰尔·斯图尔特
安德鲁·加雷思·威利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Elegant Pharmaceutical Co Ltd
Original Assignee
British Elegant Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Elegant Pharmaceutical Co Ltd filed Critical British Elegant Pharmaceutical Co Ltd
Publication of CN108883101A publication Critical patent/CN108883101A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780009979.0A 2016-02-05 2017-02-06 野靛碱的琥珀酸盐及其用途 Pending CN108883101A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1602145.3 2016-02-05
GBGB1602145.3A GB201602145D0 (en) 2016-02-05 2016-02-05 Salt
PCT/GB2017/050294 WO2017134468A1 (en) 2016-02-05 2017-02-06 Succinate salt of cytisine and use thereof

Publications (1)

Publication Number Publication Date
CN108883101A true CN108883101A (zh) 2018-11-23

Family

ID=55641904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780009979.0A Pending CN108883101A (zh) 2016-02-05 2017-02-06 野靛碱的琥珀酸盐及其用途

Country Status (17)

Country Link
US (1) US10300050B2 (enExample)
EP (2) EP3411029B1 (enExample)
JP (4) JP6820344B2 (enExample)
KR (4) KR20180121900A (enExample)
CN (1) CN108883101A (enExample)
AU (2) AU2017215300B2 (enExample)
CA (1) CA3013454C (enExample)
DK (1) DK3411029T3 (enExample)
ES (1) ES2963451T3 (enExample)
GB (2) GB201602145D0 (enExample)
MX (1) MX372607B (enExample)
PL (1) PL3411029T3 (enExample)
PT (1) PT3411029T (enExample)
SI (1) SI3411029T1 (enExample)
SM (1) SMT202300416T1 (enExample)
WO (1) WO2017134468A1 (enExample)
ZA (1) ZA201805296B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116509857A (zh) * 2023-04-11 2023-08-01 广州医科大学 金雀花碱的新应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
US11459328B2 (en) 2017-07-24 2022-10-04 Achieve Pharma Uk Limited Cytisine salts
EP3598968A1 (en) * 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
US11083715B2 (en) * 2019-09-12 2021-08-10 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101428021A (zh) * 2007-11-09 2009-05-13 江苏中康药物科技有限公司 一种用于戒除烟瘾酒瘾的外用药物制剂
WO2014076680A1 (en) * 2012-11-19 2014-05-22 Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia Solid dosage form comprising micronized cytisine
WO2015025718A1 (ja) * 2013-08-23 2015-02-26 久光製薬株式会社 貼付剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698224A (en) 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
WO1996027303A1 (en) 1995-03-06 1996-09-12 Lectec Corporation Nicotine-free smoking material
US6235734B1 (en) 1996-10-30 2001-05-22 Pfizer Inc Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
RU2228179C2 (ru) 2002-07-22 2004-05-10 Институт органической химии Уфимского научного центра РАН Гидрохлорид n-(бета-гидроксиэтил)цитизина, проявляющий антиаритмическую активность
US20050159471A1 (en) 2003-05-14 2005-07-21 Pharmacia Corporation Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20100048606A1 (en) * 2006-03-29 2010-02-25 Georgetown University Office of Technology Commercialization 10-Substituted Cytisine Derivatives and Methods of Use Thereof
US9233109B2 (en) 2010-04-23 2016-01-12 University Of Florida Research Foundation, Inc. Compositions, methods of use, and methods of treatment
CN102167680B (zh) 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
BR112013032415B1 (pt) * 2011-06-17 2021-07-27 Pfizer Anti-Infectives Ab Processos para preparar compostos e compostos
CN103044423B (zh) 2012-01-11 2013-10-23 上海合全药物研发有限公司 取代的吡啶-2-酮类化合物及其制备方法
CN103509021B (zh) 2012-06-21 2016-08-17 天津药明康德新药开发有限公司 金雀花碱衍生物及其制备方法和抗癌作用研究
FR2992315B1 (fr) 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
US20170209415A1 (en) 2012-08-13 2017-07-27 Anthony Alexander McKINNEY Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive disorders including nicotine addiction
CN102952134B (zh) 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
CN103284319A (zh) 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
GB201315030D0 (en) * 2013-08-22 2013-10-02 Knight Martin Magazine
CN103588773B (zh) 2013-11-07 2016-01-06 东南大学 一种金雀花碱的提取分离方法
CN104710422A (zh) * 2013-12-13 2015-06-17 上海壹志医药科技有限公司 金雀花碱衍生物
PL408608A1 (pl) 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
PL409830A1 (pl) 2014-10-18 2016-04-25 Łukasz Zalewski Papieros z cytyzyną
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN106188057A (zh) 2016-07-21 2016-12-07 西安岳达生物科技股份有限公司 一种金雀花碱的分离提取方法
JP7178538B2 (ja) 2016-08-19 2022-11-28 ザ ユニバーシティ オブ ブリストル 化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101428021A (zh) * 2007-11-09 2009-05-13 江苏中康药物科技有限公司 一种用于戒除烟瘾酒瘾的外用药物制剂
WO2014076680A1 (en) * 2012-11-19 2014-05-22 Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia Solid dosage form comprising micronized cytisine
WO2015025718A1 (ja) * 2013-08-23 2015-02-26 久光製薬株式会社 貼付剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116509857A (zh) * 2023-04-11 2023-08-01 广州医科大学 金雀花碱的新应用

Also Published As

Publication number Publication date
CA3013454A1 (en) 2017-08-10
KR20250004182A (ko) 2025-01-07
SI3411029T1 (sl) 2024-04-30
PT3411029T (pt) 2023-11-30
EP4265298A2 (en) 2023-10-25
AU2017215300B2 (en) 2022-03-03
GB2550241A (en) 2017-11-15
EP4265298A3 (en) 2024-01-10
SMT202300416T1 (it) 2024-01-10
JP2019504848A (ja) 2019-02-21
PL3411029T3 (pl) 2024-01-29
US20190038608A1 (en) 2019-02-07
GB201602145D0 (en) 2016-03-23
GB201701939D0 (en) 2017-03-22
KR20180121900A (ko) 2018-11-09
KR20240042257A (ko) 2024-04-01
JP7292316B2 (ja) 2023-06-16
NZ744953A (en) 2024-11-29
EP3411029B1 (en) 2023-11-01
JP2025038099A (ja) 2025-03-18
GB2550241B (en) 2018-04-25
MX372607B (es) 2020-04-30
ES2963451T3 (es) 2024-03-27
CA3013454C (en) 2020-02-25
ZA201805296B (en) 2019-04-24
US10300050B2 (en) 2019-05-28
EP3411029A1 (en) 2018-12-12
JP6820344B2 (ja) 2021-01-27
WO2017134468A1 (en) 2017-08-10
MX2018009364A (es) 2019-05-15
AU2022203808B2 (en) 2023-10-19
JP2021073197A (ja) 2021-05-13
AU2022203808A1 (en) 2022-06-23
KR20250078632A (ko) 2025-06-02
DK3411029T3 (da) 2023-11-27
JP2023113803A (ja) 2023-08-16
AU2017215300A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
JP7292316B2 (ja) シチシンのコハク酸塩およびその使用
AU2011278451B2 (en) Aqueous composition comprising bromhexine
KR101915056B1 (ko) 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법
JP7178158B2 (ja) シチシン塩、シチシン塩の溶媒和物または水和物、シチシン塩の製造方法、医薬組成物、および治療方法
EP4309642A1 (en) Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same
TWI689306B (zh) 經安定化而成之醫藥組成物
JP4727990B2 (ja) モルヒネ−６−グルクロニドの塩
HK40093180A (en) Salt
CN113195453B (zh) 异喹啉磺酰胺的新形态
EP4420664A1 (en) Pharmaceutical composition comprising cytisine
TW202532060A (zh) 醫藥組成物
WO2025115989A1 (ja) 医薬組成物
HK40048071A (en) Novel form of isoquinolinesulfonamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123